<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783183</url>
  </required_header>
  <id_info>
    <org_study_id>YHD1119-103</org_study_id>
    <nct_id>NCT02783183</nct_id>
  </id_info>
  <brief_title>A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin</brief_title>
  <official_title>A Open-label, Radomized, Crossover Clinical Trial to Assess the Pharmacokinetics of Pregabalin CR After Multiple Dosing as Compared to Pregabalin IR in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial to compare the pharmacokinetic characteristics of
      YHD1119(Pregabalin 300mg) and Lyrica capsule(Pregabalin 150mg). YHD1119 is controlled release
      formulation which is made by Yuhan Corporation. Primary endpoints are Cmax,ss and AUCtau and
      secondary endpoints are AUClast,ss, AUCinf,ss, Tmax,ss and t1/2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau</measure>
    <time_frame>0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast,ss</measure>
    <time_frame>0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf,ss</measure>
    <time_frame>0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss</measure>
    <time_frame>0.33,0.67,1,2,4,8,12,12.33,12.67,13,14,16,20,24,36 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Peripheral Nueropathy Pain</condition>
  <arm_group>
    <arm_group_label>YHD1119</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregabalin 300mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lyrica</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregabalin 150mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHD1119</intervention_name>
    <description>2 by 2</description>
    <arm_group_label>YHD1119</arm_group_label>
    <arm_group_label>Lyrica</arm_group_label>
    <other_name>Pregabalin 300mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lyrica</intervention_name>
    <description>2 by 2</description>
    <arm_group_label>YHD1119</arm_group_label>
    <arm_group_label>Lyrica</arm_group_label>
    <other_name>Pregabalin 150mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19~50 years old, healthy male volunteers

          -  &gt;55Kg(Body weight) and 18.5&lt;BMI&lt;28

        Exclusion Criteria:

          -  AST or ALT &gt; 3 * Upper normal range (Lab)

          -  Total bilirubin &gt; 2.0 mg/dl

          -  Systolic BP &gt;140 OR &lt;90, Diastolic BP &gt;100 OR &lt;60
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

